Commercial Due Diligence
When evaluating pharma, biotech, or MedTech investments, commercial viability is often the make-or-break factor. Dr. Kurr provides commercial due diligence that goes beyond market sizing and competitive landscape - assessing organizational readiness, go-to-market capability, content and channel operations maturity, and scalability of the commercial model. His 20+ years operating inside top pharma companies provides pattern recognition that identifies risks and opportunities invisible to desk-based analysis.
Portfolio Company Advisory
Post-investment, portfolio companies need hands-on commercial and operational guidance to achieve their growth targets. As an operating partner or venture partner model, Dr. Kurr embeds within portfolio companies to accelerate commercial readiness - from market access and pricing strategy to sales organization design and launch planning. His fractional CCO model at Lemna Bio demonstrates exactly this approach: providing C-level commercial capability to a computational drug design company without the overhead of a full-time hire.
Market Access & Pricing Assessment
For investors evaluating therapeutic or diagnostic assets, understanding the reimbursement landscape and pricing potential is critical to investment thesis validation. Dr. Kurr assesses market access strategies, payer engagement plans, and health economics positioning - translating complex regulatory and commercial dynamics into investor-friendly frameworks for decision-making.
Board Service & Strategic Governance
Investors increasingly seek board members who combine operational expertise with strategic perspective. Dr. Kurr serves on advisory boards providing governance, commercial strategy guidance, and operational oversight. His academic foundation - doctorate from University of St. Gallen and executive certifications from MIT Sloan and IMD - complements his practitioner experience, offering boards the rigorous, evidence-based perspective they need for critical decisions.